Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) PT at $57.73

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMGet Free Report) has received an average rating of “Buy” from the eleven analysts that are currently covering the stock, Marketbeat.com reports. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $57.10.

A number of research analysts have recently commented on the company. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. HC Wainwright reiterated a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners raised their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, Citigroup boosted their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th.

Check Out Our Latest Stock Analysis on MIRM

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $41.13 on Friday. The company has a market capitalization of $1.97 billion, a PE ratio of -20.36 and a beta of 1.20. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals has a one year low of $23.14 and a one year high of $48.89. The company’s fifty day moving average price is $42.15 and its 200 day moving average price is $39.12.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same period in the previous year, the company posted ($0.57) earnings per share. The firm’s revenue for the quarter was up 89.4% on a year-over-year basis. As a group, analysts expect that Mirum Pharmaceuticals will post -1.48 earnings per share for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,500 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the sale, the senior vice president now directly owns 2,426 shares in the company, valued at $114,264.60. This represents a 50.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 22.87% of the stock is owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC grew its holdings in shares of Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after purchasing an additional 1,127 shares during the last quarter. Amalgamated Bank raised its stake in shares of Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after buying an additional 513 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after acquiring an additional 318 shares during the last quarter. ProShare Advisors LLC acquired a new position in Mirum Pharmaceuticals in the second quarter valued at about $213,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at approximately $215,000.

Mirum Pharmaceuticals Company Profile

(Get Free Report

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Featured Stories

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.